Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study
Dong-Ho Song, Soul Choi, Yoo Sook Joung, Eun Hye Ha, Boong-Nyun Kim, Yee-Jin Shin, Dongwon Shin, Hee Jeong Yoo, Keun-Ah Cheon
Psychiatry Investig. 2012;9(3):257-262.   Published online 2012 Sep 6     DOI: https://doi.org/10.4306/pi.2012.9.3.257
Evaluation of Methylphenidate Safety and Maximum-Dose Titration Rationale in Attention-Deficit/Hyperactivity Disorder
Cellina Ching, Guy D. Eslick, Alison S. Poulton
JAMA Pediatrics.2019; 173(7): 630.     CrossRef
Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies
Ole Jakob Storebø, Nadia Pedersen, Erica Ramstad, Maja Laerke Kielsholm, Signe Sofie Nielsen, Helle B Krogh, Carlos R Moreira-Maia, Frederik L Magnusson, Mathilde Holmskov, Trine Gerner, Maria Skoog, Susanne Rosendal, Camilla Groth, Donna Gillies, Kirsten
Cochrane Database of Systematic Reviews.2018;[Epub]     CrossRef
Remission Rate and Functional Outcomes During a 6-Month Treatment With Osmotic-Release Oral-System Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder
Yi Su, Haibo Li, Yixin Chen, Fang Fang, Tong Xu, Haiping Lu, Ling Xie, Jianmin Zhuo, Jiazhi Qu, Li Yang, Yufeng Wang
Journal of Clinical Psychopharmacology.2015; 35(5): 525.     CrossRef
The Effect of Methylphenidate on Neurological Soft Signs in ADHD
Igor Hrtanek, Igor Ondrejka, Ingrid Tonhajzerova, Eva Snircova, Tomas Kulhan, Ivan Farsky, Gabriela Nosalova
Psychiatry Investigation.2015; 12(4): 545.     CrossRef
Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain-derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder
Serkan Sahin, Murat Yuce, Hasan Alacam, Koray Karabekiroglu, Gokce Nur Say, Osman Salıs
International Journal of Psychiatry in Clinical Practice.2014; 18(4): 280.     CrossRef
A Review of OROS Methylphenidate (Concerta®) in the Treatment of Attention-Deficit/Hyperactivity Disorder
Martin A. Katzman, Tia Sternat
CNS Drugs.2014; 28(11): 1005.     CrossRef